Search
Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive...
Sep 2
SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more
He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in...
Jan 16
Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result
Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.
Dec 27, 2023
Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December
President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' 25 years.
Nov 20, 2023
.png){kind=logo}
